# Use of a Combined Regimen of Fluoxetine, Prednisolone and Ivermectin in the Treatment of Mild COVID-19 to Prevent Disease Progression Progression in Papua New Guinea

> **NCT05283954** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Oriol Mitja**

## Conditions studied

- SARS-CoV2 Infection
- COVID-19

## Interventions

- **DRUG:** Combination regimen: Fluoxetine, Prednisolone, Ivermectin
- **DRUG:** Combination regimen: Albendazole, Vitamin C

## Key facts

- **NCT ID:** NCT05283954
- **Lead sponsor:** Oriol Mitja
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-05-01
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-07-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2023-03-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05283954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05283954, "Use of a Combined Regimen of Fluoxetine, Prednisolone and Ivermectin in the Treatment of Mild COVID-19 to Prevent Disease Progression Progression in Papua New Guinea". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05283954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*